ALT
Altimmune, Inc.
Altimmune (ALT) Q2 2026 earnings
Published Aug 12, 2026
AI summary
- GAAP EPS −$0.12, up from −$0.27 a year ago.
- Altimmune reported a net loss of $22.8 million for the second quarter of 2026.
- The company ended the quarter with $519 million in cash, cash equivalents, and investments.
- Research and development expenses rose to $18.7 million, driven by ongoing clinical trial activities.
- The company initiated a Phase 3 trial for MASH and reported positive Phase 2 data for its AUD treatment.
Results vs analyst consensus
Revenue
Not reported in this release.
EPS · GAAP
Reported · GAAP diluted EPS
−$0.12
Consensus not captured before release
Prior year: −$0.27
Consensus: Yahoo Finance · Q2 2026
Revenue display rounded; difference uses exact result.
Next quarter outlook
No guidance in this release.
What to watch
- The company reported no revenue for the second quarter of 2026.
- Operating expenses increased compared to the same period in 2025 due to higher R&D and administrative costs.
Read original report
Source: Altimmune, Inc. press release · SEC Form 8-K exhibit 99.1